According to GuruFocus Insider Data, these are the largest CEO buys during the past week.
Ulta CEO bought 1,300 shares
Ulta Beauty Inc. (ULTA, Financial) CEO Mary N. Dillon bought 1,300 shares on Sept. 26 at a price of $237.17. The price of the stock has increased by 3.05% since then.
Ulta is a North American beauty retailer for cosmetics, skin-care products, fragrance, hair-care products and salon services. The company offers products from over 500 beauty brands across all categories and price points, including its own private label. Additionally, Ulta offers full-service salon in every store, featuring hair, skin and brow services. Its stores are predominantly located in convenient and high-traffic locations. A typical Ulta store has more than 20,000 prestige, mass and professional beauty products. The company has a market cap of $14.38 billion. Its shares traded at $244.40 with a price-earnings ratio of 20.71 as of Sept. 27.
Net income for the second quarter of 2019 was $161.3 million, compared to $148.3 million in the second quarter of fiscal 2018.
Envista Holdings CEO bought 10,000 shares
Envista Holdings Corp. (NVST, Financial) President and CEO Amir Aghdaei bought 10,000 shares on Sept. 20 at a price of $22.00. The price of the stock has increased by 20.86% since then.
Envista is a global dental products company that develops and provides a comprehensive portfolio of dental consumables, equipment and services to dental professionals covering an estimated 90% of dentists' clinical needs for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. Envista's operating companies, Nobel Biocare Systems, Ormco and KaVo Kerr, serve more than 1 million dentists in over 150 countries. Envista is a subsidiary of Danaher Corp. (DHR). Envista has a market cap of $4.22 billion. Its shares traded at $26.59 as of Sept. 27.
On Sept. 20, 2019, Envista announced the closing of its previously announced initial public offering of 26,768,000 shares of its common stock at a price to the public of $22.00 per share.
Senior Vice President and Chief Financial Officer Howard H. Yu bought 2,000 shares on Sept. 20 at a price of $22. Since then, the price of the stock has increased by 20.86%.
Senior Vice President Mischa Reis bought 1,000 shares on Sept. 20 at a price of $22. The price of the stock has increased by 20.86% since then.
Senior Vice President Jeffrey Kappler bought 5,000 shares on Sept. 20 at a price of $22. Since then, the price of the stock has increased by 20.86%.
Senior Vice President Patrik Eriksson bought 5,000 shares on Sept. 20 at a price of $22. The price of the stock has increased by 20.86% since then.
Senior Vice President and Chief Human Resources Officer Curt W. Bludworth bought 5,000 shares on Sept. 20 at a price of $22. Since then, the price of the stock has increased by 20.86%.
Gossamer Bio CEO bought 10,000 shares
Gossamer Bio Inc. (GOSS, Financial) President and CEO Sheila Gujrathi bought 10,000 shares on Sept. 27 at a price of $16.80. The price of the stock has increased by 2.32% since then.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company has a market cap of $1.13 billion. Its shares traded at $17.19 as of Sept. 27.
Net loss for the second quarter of 2019 was $44.5 million.
Chief Financial Officer Bryan Giraudo bought 1,121 shares on Sept. 26 at a price of $16.78. Since then, the price of the stock has increased by 2.44%.
Executive Vice President and General Counsel Christian Waage bought 1,000 shares on Sept. 27 at a price of $16.65. The price of the stock has increased by 3.24% since then.
Director Faheem Hasnain bought 10,000 shares on Sept. 27 at a price of $16.8. Since then, the price of the stock has increased by 2.32%.
Ten-percent Owner Omega Fund V GP LP sold 112,776 shares on Sept. 11 at a price of $21.22; 82,213 shares on Sept. 18 at a price of $21.75; and 183,607 shares on Sept. 20 at a price of $21.96. The price of the stock has decreased by 21.72% since then.
Athenex CEO bought 5,000 shares
Athenex Inc. (ATNX, Financial) CEO, Chairman of the Board and 10% Owner Johnson Yiu Nam Lau bought 5,000 shares on Sept. 23 at a price of $13.86. The price of the stock has decreased by 9.31% since then.
The biopharmaceutical company is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments: Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China. The company has a market cap of $971.96 million. Its shares traded around $12.57 as of Sept. 27.
Net loss for the three months ended June 30 was $32 million, compared to a net loss of $36.9 million in the same period last year.
Lau also bought 5,000 shares on Sept. 16 at a price of $13.57. The price of the stock has decreased by 7.37% since then.
Perceptive Life Sciences Master Fund, which is a 10% owner of the stock, bought 70,000 shares on Sept. 13 for an average price of $14.23 and 30,000 shares on Sept. 16 for $13.58. Since then, the stock has decreased by 7.44%.
For the complete list of stocks bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Read more here:Â
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
